Brief: Maat Pharma Presents Promising Clinical Data From 76 Patients With Acute Graft-Versus-Host-Disease Treated With Maat013 At 63Rd Ash Annual Meeting

Maat Pharma SA

11/12/2021 20:06

Dec 11 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA PRESENTS PROMISING CLINICAL DATA FROM 76
PATIENTS
WITH ACUTE GRAFT-VERSUS-HOST-DISEASE TREATED WITH MAAT013 AT
63RD ASH ANNUAL MEETING
    * MAAT PHARMA - PRESENTATION INCLUDES RESULTS FROM HERACLES
PHASE
2 TRIAL IN 24 PATIENTS WITH STEROID-RESISTANT GRADE III-IV
GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE (GI-AGVHD)
    * MAAT PHARMA - PRESENTATION ALSO INCLUDES RESULTS FROM
COMPASSIONATE USE PROGRAM FOR MAAT013 IN FRANCE IN 52 PATIENTS
WITH GRADE II-IV GI-AGVHD HAVING FAILED PREVIOUS THERAPIES
    * PIVOTAL PHASE 3 CLINICAL TRIAL OF MAAT013 IN AGVHD IS
BEING
INITIATED

Source text for Eikon:  ID:nBw45RzlVa 
Further company coverage:  MAAT.PA 

 ((Reuters.Briefs@thomsonreuters.com;))